Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition

Next Previous
Trial Profile

A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Carcinoma; Non-small cell lung cancer; Small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms BIOLUMA

Most Recent Events

  • 04 Jun 2024 Results(n=45) evaluating the combination therapy of nivolumab and ipilimumab in TMBhigh SCLC patients , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 08 Dec 2023 Status changed from active, no longer recruiting to completed.
  • 18 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top